Effectiveness of an Interventional to Improve the Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention: Randomized Clinical Trial (Adequacy of Lipid Treatment)

First published: 24/01/2014

Last updated: 12/02/2014

Study Ongoing

Administrative details

EU PAS number

EUPAS5668

Study ID

5820

DARWIN EU® study

No

Study countries

Spain

Study description

To evaluated the impact of an interention addressed to health professionals to improve the adequacy of lipid-lowering prescription in primary prevention of cardiovascular disease and reducing expenditure in this respect.

Study status

Ongoing

Research institutions and networks

Institutions

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

Spain

First published: 05/10/2012

Last updated: 23/05/2025

Institution | **Educational Institution** | **Laboratory/Research/Testing facility** | **Not-for-profit** | **ENCePP partner**

Contact details

Study institution contact

Bonaventura Bolíbar bbolibar@idiapjgol.org

Study contact

bbolibar@idiapjgol.org

Primary lead investigator

Bonaventura Bolíbar

Primary lead investigator

Study timelines

Date when funding contract was signed
Actual: 31/01/2012

Study start date
Actual: 30/09/2013

Data analysis start date
Actual: 02/12/2013

Date of final study report
Planned: 30/06/2014

Sources of funding

- Other

More details on funding

Ayuda para el fomento de la investigación clínica independiente. Ministerio de SAnidad SErvicios Sociales e Igualdad

Regulatory

Was the study required by a regulatory body?

Unknown

Methodological aspects

Study type

Study type list

Study type:

Clinical trial

Scope of the study:

Drug utilisation

Main study objective:

To evaluate the impact of an international addressed to health professionals to improve the adequacy of lipid-lowering prescription in primary prevention of cardiovascular disease and reducing expenditure in the respect

Study Design

Clinical trial randomisation

Randomised clinical trial

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(C10AA) HMG CoA reductase inhibitors

HMG CoA reductase inhibitors

Population studied

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)

Estimated number of subjects

120000

Study design details

Outcomes

1.Description of demographic and clinical characteristics of patients with new lipid-lowering therapy.2. To know the adequacy of lipid-lowering therapy in patients with treatment for primary prevention (no history of cardiovascular disease).3. To Identify factors related to adequate pharmacological lipid-lowering treatment in primary prevention.4. To analyze the level of cardiovascular risk

---

Data analysis plan

To assess the effect of the intervention model multilevel logistic regression analysis considering as dependent variable group intervention / control, adjusting for potential independent predictor variables and those considered clinically relevant, adjusting for baseline values were performed

Data management

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

The Information System for Research in Primary Care (SIDIAP)

Data sources (types)

Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No